AlphaStreet Newsdesk powered by AlphaStreet Intelligence
STTK|EPS -$0.13|Rev $0|Web Loss $14.8M
Shattuck Labs Inc. (STTK) reported a Q1 2026 primary and diluted lack of $0.13 per share because the scientific-stage biotechnology firm continued to function with out producing income. The corporate posted a internet lack of $14.8M for the interval.
It didn’t generate any income for the quarter, according to the prior 12 months interval, reflecting the corporate’s standing as a improvement-stage biopharmaceutical agency targeted on advancing its pipeline somewhat than commercializing merchandise.
Shattuck Labs develops novel biologics for the remedy of most cancers and autoimmune illness. The corporate’s proprietary Agonist Redirected Checkpoint platform is designed to beat limitations of standard immunotherapies. Like many pre-income biotechnology firms, Shattuck depends on scientific trial progress and partnership alternatives somewhat than product gross sales as it really works to advance its therapeutic candidates by improvement phases.
The outcomes underscore the monetary profile typical of scientific-stage biotech companies, the place working bills associated to analysis, improvement, and scientific trials drive losses whereas the corporate builds its portfolio forward of potential commercialization. Shattuck’s efficiency displays the prolonged improvement timelines inherent in bringing novel biologics from laboratory analysis by human trials towards regulatory approval.
This content material is for informational functions solely and shouldn’t be thought of funding recommendation. AlphaStreet Intelligence analyzes monetary knowledge utilizing AI to ship quick and correct market info. Human editors confirm content material.
Source link
#Shattuck #Labs #Releases #Financial #Results #Alphastreet
